The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LPTX | -86.62% | -97.16% | -50.94% | -99% |
| S&P | +14.08% | +93.57% | +14.12% | +198% |
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $12.30M | -83.6% |
| Market Cap / Employee | $0.24M | 0.0% |
| Employees | 52 | -3.7% |
| Net Income | -$16.64M | 17.3% |
| EBITDA | -$12.35M | 41.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.13M | -76.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.28M | -35.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -129.47% | -61.7% |
| Return On Invested Capital | -103.50% | -588.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14.49M | -6.0% |
| Operating Free Cash Flow | -$14.49M | -6.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.49 | 2.25 | 0.33 | 0.59 | -44.27% |
| Price to Tangible Book Value | 1.49 | 2.25 | 0.33 | 0.59 | -44.27% |
| Enterprise Value to EBITDA | -2.43 | -4.44 | 1.23 | 0.45 | 624.00% |
| Return on Equity | -106.8% | -141.9% | -202.8% | -183.7% | 129.00% |
| Total Debt | $0.38M | $0.27M | $0.52M | $0.28M | -41.08% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
